23 48

Cited 0 times in

Effect of Intravitreal Bevacizumab Injection before Panretinal Photocoagulation on the Prevention of Macular Edema Aggravation in Proliferative Diabetic Retinopathy

DC FieldValueLanguage
dc.contributor.author강현구-
dc.contributor.author고형준-
dc.contributor.author김민-
dc.contributor.author김성수-
dc.contributor.author최웅락-
dc.contributor.author최은영-
dc.date.accessioned2021-01-19T07:57:54Z-
dc.date.available2021-01-19T07:57:54Z-
dc.date.issued2020-11-
dc.identifier.urihttps://ir.ymlib.yonsei.ac.kr/handle/22282913/181395-
dc.description.abstractObjective: To investigate the effects of intravitreal bevacizumab (IVB) injection before PRP on the prevention of macular edema (ME) in patients with PDR. Methods: This retrospective observational study included patients diagnosed with PDR treated by PRP with (combination group) or without (PRP alone group) preoperative IVB injection (1.25 mg/0.05 mL). The primary outcome measure was the change in the central macular thickness (CMT), while the secondary outcome measure was the change in visual acuity. Measurements were made before and at one, two, and three months after treatment. Results: In the PRP alone group, the mean baseline CMT of 277.8 μm increased to 290.4 μm at one month (p = 0.201) and 308.8 μm at two months (p = 0.002), followed by a decrease to 271.2 μm at three months (p = 0.437). In the combination group, the values at baseline and one, two, and three months after PRP were 322.9 μm, 295.4 μm (p = 0.002), 330.1 μm (p = 0.906), and 274.5 μm (p = 0.030), respectively. Visual acuity changes were comparable between the two groups at all time points. Conclusion: IVB injection before PRP leads to decreased CMT in comparison to CMT in patients with PRP alone.-
dc.description.statementOfResponsibilityopen-
dc.languageEnglish-
dc.publisherMDPI AG-
dc.relation.isPartOfJOURNAL OF CLINICAL MEDICINE-
dc.rightsCC BY-NC-ND 2.0 KR-
dc.titleEffect of Intravitreal Bevacizumab Injection before Panretinal Photocoagulation on the Prevention of Macular Edema Aggravation in Proliferative Diabetic Retinopathy-
dc.typeArticle-
dc.contributor.collegeCollege of Medicine (의과대학)-
dc.contributor.departmentDept. of Ophthalmology (안과학교실)-
dc.contributor.googleauthorWungrak Choi-
dc.contributor.googleauthorHyun Goo Kang-
dc.contributor.googleauthorEun Young Choi-
dc.contributor.googleauthorSung Soo Kim-
dc.contributor.googleauthorHyoung Jun Koh-
dc.contributor.googleauthorMin Kim-
dc.identifier.doi10.3390/jcm9113772-
dc.contributor.localIdA04873-
dc.contributor.localIdA00152-
dc.contributor.localIdA00152-
dc.contributor.localIdA00455-
dc.contributor.localIdA00455-
dc.contributor.localIdA00571-
dc.contributor.localIdA00571-
dc.contributor.localIdA04123-
dc.contributor.localIdA04123-
dc.contributor.localIdA05056-
dc.contributor.localIdA05056-
dc.relation.journalcodeJ03556-
dc.identifier.eissn2077-0383-
dc.identifier.pmid33238391-
dc.subject.keywordcentral macular thickness-
dc.subject.keywordintravitreal bevacizumab-
dc.subject.keywordmacular edema-
dc.subject.keywordpanretinal photocoagulation-
dc.subject.keywordproliferative diabetic retinopathy-
dc.contributor.alternativeNameKang, Hyun Goo-
dc.contributor.affiliatedAuthor강현구-
dc.contributor.affiliatedAuthor고형준-
dc.contributor.affiliatedAuthor고형준-
dc.contributor.affiliatedAuthor김민-
dc.contributor.affiliatedAuthor김민-
dc.contributor.affiliatedAuthor김성수-
dc.contributor.affiliatedAuthor김성수-
dc.contributor.affiliatedAuthor최웅락-
dc.contributor.affiliatedAuthor최웅락-
dc.contributor.affiliatedAuthor최은영-
dc.contributor.affiliatedAuthor최은영-
dc.citation.volume9-
dc.citation.number11-
dc.citation.startPage3772-
dc.identifier.bibliographicCitationJOURNAL OF CLINICAL MEDICINE, Vol.9(11) : 3772, 2020-11-
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Ophthalmology (안과학교실) > 1. Journal Papers

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.